Journal article
Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials
Abstract
BACKGROUND: We hypothesized that increased baseline BMI and BMI change would negatively impact clinical outcomes with adjuvant breast cancer systemic therapy.
METHODS: Data from chemotherapy trials MA.5 and MA.21; endocrine therapy MA.12, MA.14 and MA.27; and trastuzumab HERA/MA.24 were analyzed. The primary objective was to examine the effect of BMI change on breast cancer-free interval (BCFI) landmarked at 5 years; secondary objectives …
Authors
Yerushalmi R; Dong B; Chapman JW; Goss PE; Pollak MN; Burnell MJ; Levine MN; Bramwell VHC; Pritchard KI; Whelan TJ
Journal
Annals of Oncology, Vol. 28, No. 7, pp. 1560–1568
Publisher
Elsevier
Publication Date
July 2017
DOI
10.1093/annonc/mdx152
ISSN
0923-7534